Antonino Musolino

机构：Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituti di Ricovero e Cura a Carattere Scientifico, University of Bologna · ORCID：0000-0002-7979-6261

发表论文 377 篇 · 总被引 5552 次 · h-index 34

代表论文

• A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients (2025 · Annals of Oncology · 被引 10)
• Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity (2025 · Experimental Hematology and Oncology · 被引 5)
• Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications (2025 · npj Breast Cancer · 被引 3)
• Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions (2025 · Cancers · 被引 3)
• Cardiovascular toxicities reported with Poly ADP Ribose Polymerase (PARP) inhibitors in the FDA Adverse Event Reporting System (2025 · European Heart Journal Supplements · 被引 3)
• A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study (2026 · Annals of Oncology · 被引 2)